Showing posts with label Dr. Albert Bourla. Show all posts
Showing posts with label Dr. Albert Bourla. Show all posts

Friday, June 30, 2023

Just as Improvac ultimately targets gonadotropin-releasing hormone as a way to “castrate” male pigs, . . . it turns out the infamous spike protein from SARS-CoV-2—the virus that supposedly causes COVID-19—also targets GnRH.


Just as Improvac ultimately targets gonadotropin-releasing hormone as a way to “castrate” male pigs or suppress ovarian function in female pigs, it turns out the infamous spike protein from SARS-CoV-2—the virus that supposedly causes COVID-19—also targets GnRH.



In the video above from 2009, Bourla touts “Improvac,” which he claims is “the world’s first vaccine for the control of boar taint.” And while the endpoint of efficacy for the “vaccine” is the elimination of “boar taint”—that is, the offensive odor or taste that can be evident during the cooking or eating of pork or pork products derived from non-castrated male pigs—he notes “its efficacy is… as good as… physical castration.”

Bourla goes on to note the injection “exceeds 99% of success” and went through 130 clinical trials(!!!).

As the European Medicines Agency (EMA) notes in the excerpt immediately below, Improvac is “an immunological medicine” that aims to mitigate the natural production and build-up of androstenone and skatole. Androstenone is a steroidal pheromone that’s found in male boars’ saliva. Skatole is a byproduct of intestinal bacteria or bacterial metabolite of the amino acid tryptophan. (Note: It’s unclear why Bourla refers to Improvac as a “vaccine” while the EMA refers to it as a “medicine.”)

To prevent the buildup of androstenone and skatole, “Improvac is used as an alternative to physical castration (removal of the testes) to reduce the presence of these compounds,” in turn, also reducing “aggressive and sexual (mounting) behavior in pigs.”


What is Improvac and what is it used for?  Improvac is an immunological medicine used in male pigs to reduce 'bore taint' in the meat obtained from them after slaughter.  Boar taint is the offensive odor or taste which may be present in pork or pork products from non-castrated mature male pigs.  Boar taint is caused by the production and build-up of the natural compounds androstenone and skatole in the fat of these animals.  Improvac is used as an alternative to physical castration removal of the testes to reduce the presence of these compounds.  Improvac also reduces aggressive and sexual mounting behavior in pigs. 

Improvac can also be used in female pigs from 14 weeks of age intended for market to temporarily suppress ovarian function (suppression of oestrus) in order to reduce the number of unwanted pregnancies in gilts intended for slaughter and to reduce the associated sexual behavior (standing oestrus).

Improvac contains the active substance gonadotropin-releasing factor GnRF analog-protein conjugate. 

PFIZER ANIMAL HEALTH?  UH-OH
SO WE'RE ALREADY CONSUMING VACCINES FROM MEAT . . . .  OH, WONDERFUL

Link to EMA document

The EMA also notes that Improvac can be used in female pigs, where it’s intended… to temporarily suppress ovarian function (suppression of oestrus) in order to reduce the number of unwanted pregnancies…” (Oestrus is the period in the sexual cycle of female mammals.)

In the video immediately below from Pfizer Animal Health, posted to YouTube by animalpharmnews in 2009, the way Improvac works in the male boar’s body is described and shown. We see that the way the “vaccine” (or “medicine”) works to mitigate androstenone and skatole (although more circuitously in the latter compound’s case), is by delivering “an antigen” that mimicks GnRH; that is, gonadotropin-releasing hormone. This is referred to as a “GnRH analogue.”

As the video shows, GnRH is responsible for the “cascade” of chemicals that leads to the release of androstenone and testosterone from the testes when it itself is released from the hypothalamus, travels through the bloodstream, and arrives at the pituitary gland, where it binds to a specific GnRH receptor. Once the GnRH binds to the receptor, there’s a release of two hormones—luteinizing hormone (LH) and follicle-stimulating hormone (FSH). These two hormones then travel to the testes, where they trigger the release of androstenone and testosterone.

Keep reading . . . 



Tuesday, October 11, 2022

PFIZER'S PRESIDENT OF INT'L DEVELOPED MARKETS SAYS, "We had to really move at the speed of science to really understand what [was] taking place in the market."

Her name is Janine Small, and she is the President of International Developed Markets at Pfizer.

Her audience is the EU Parliament, so this is like singing to the choir.  Her interrogator is Rob Roos, an MEP.

Roos:  Was the Pfizer COVID vaccine tested on stopping the transmission of the virus before it entered the market?  If not, please say it clearly.  If yes, are you willing to share the data with this committee?  And I really want straight answer, yes or no, and I am looking forward to it.  Thank you very much. 

Small, 0:35:  Um, regarding the question around, um, "Did we know about stopping immunization before it entered the market?"  No [she laughs].  We had to really move at the speed of science to really understand what [was] taking place in the market.  

And from that point of view, we had to do everything at risk.  I think it was Dr. [Albert] Bourla, even though he's not here, would turn around and say to you himself that "If not us, then who?"  Dr. Bourla actually felt the importance of what was going on in the world.  ["felt"?]  And therefore, as a result of that, we actually spent $2 billion dollars at risk of self-funded money from Pfizer [I believe countries around the world indemnified the vaccine manufacturers, meaning no risk to them] to be able to manufacture . . . first of all, research, develop, and manufacture at risk to be able to make sure that we were in a position to be able to help with the pandemic.  And I think that's why I feel very good when a recent paper from the Imperial College [and here, and owned and operated by Bill Gates' money] stated that in the first year of the rollout of vaccines we saved 4 million people.  So from that point of view, I feel, actually that we were there.  (Could she be more vague; could she say less than nothing by saying more than wanted?) when the world needed us.  (Wow, I don't remember thinking that I needed her or Pfizer or the Imperial College, do you?) to be able to make sure that we were able to help people around the world with vaccination as well as oral treatment.  I would hate to imagine what situation we would be in the world right now if companies like ours did not take those risks, did not do clinical research [you didn't do clinical research] and development at scale in order to have a vaccine that we could rollout to the world.  I understand your frustrations, I really do, but I also hope that at some point, somewhere you also do appreciate what pharmaceutical companies have done to rollout and deliver vaccines at such speed and scale. 

Since we're talking about scale, Ms. Small, did Imperial College or Dr. Bourla inform you these numbers, these global numbers?